Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment
VIR•Analyst view
The current average analyst rating on the shares is buy, with 10 strong buy or buy recommendations, no hold, and no sell or strong sell ratings.
The median 12-month price target for Vir Biotechnology, Inc. is $21.00, about 129% above its August 4 closing price of $9.17.
Outlook and pipeline timeline
Vir expects topline data from the Phase 3 ECLIPSE 1 trial in Q4 2026.
The company also anticipates initiating pivotal Phase 3 trials for VIR-5500 in 2027.
Vir said its cash and investments are expected to fund operations into the second half of 2028.
Q2 revenue rises on Astellas payment
Vir Biotechnology's second-quarter revenue rose sharply and beat analyst expectations, driven primarily by a $240 million upfront payment from its collaboration with Astellas.
The company reported , compared with the consensus estimate of from five analysts.
